Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] stock went on an upward path that rose over 7.47% on Thursday, amounting to a one-week price increase of more than 8.96%.
Over the last 12 months, AUPH stock dropped by -3.90%. The one-year Aurinia Pharmaceuticals Inc stock forecast points to a potential downside of -12199900.0. The average equity rating for AUPH stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.17 billion, with 137.75 million shares outstanding and 119.37 million shares in the current float. Compared to the average trading volume of 1.22M shares, AUPH stock reached a trading volume of 3510251 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Aurinia Pharmaceuticals Inc [AUPH]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AUPH shares is $10.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUPH stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Aurinia Pharmaceuticals Inc shares, keeping their opinion on the stock as Perform, with their previous recommendation back on November 04, 2022. While these analysts kept the previous recommendation, Cantor Fitzgerald dropped their target price from $34 to $25. The new note on the price target was released on May 05, 2022, representing the official price target for Aurinia Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $33 to $31, while Oppenheimer kept a Outperform rating on AUPH stock.
The Price to Book ratio for the last quarter was 3.39, with the Price to Cash per share for the same quarter was set at 2.32. Price to Free Cash Flow for AUPH in the course of the last twelve months was 18.48 with Quick ratio for the last quarter at 5.26.
AUPH Stock Performance Analysis:
Aurinia Pharmaceuticals Inc [AUPH] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.96. With this latest performance, AUPH shares gained by 5.89% in over the last four-week period, additionally sinking by -4.43% over the last 6 months – not to mention a drop of -3.90% in the past year of trading.
Insight into Aurinia Pharmaceuticals Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Aurinia Pharmaceuticals Inc [AUPH] shares currently have an operating margin of 21.26% and a Gross Margin at 88.24%. Aurinia Pharmaceuticals Inc’s Net Margin is presently recorded at 16.11%.
Return on Equity for this stock inclined to 7.80%, with Return on Assets sitting at 7.80%.
Aurinia Pharmaceuticals Inc [AUPH] Institutonal Ownership Details
The top three institutional holders of AUPH stocks are: ARMISTICE CAPITAL, LLC with ownership of 11.14 million shares, which is approximately 7.7696%. BLACKROCK INC., holding 9.27 million shares of the stock with an approximate value of $$52.94 million in AUPH stocks shares; and BLACKROCK INC., currently with $$22.67 million in AUPH stock with ownership which is approximately 2.7698%.
